Generate Biomedicines (GENB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $12.09, -7.43% vs the prior close of $13.06.
- Volume 1.07M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GENB slides 7.4% to $12.09, a 3-month low. Closed at $12.09, -7.43% vs the prior close of $13.06. Day range $11.84–$13.22, opened at $13.02.
GENB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GENB slides 7.4% to $12.09, a 3-month low
- Closed at $12.09, -7.43% vs the prior close of $13.06. Day range $11.84–$13.22, opened at $13.02.
- Volume was 1.07M shares, 0.9x its 50-day average of 1.26M.
- Price is -21.4% vs its 50-day average ($15.37).
- 52-week range $11.00–$22.67; today's close sits at 9% of that range, 46.7% below the 52-week high.
Oct 15, 2026 — GENB jumps 4.3% to $13.06
- Closed at $13.06, +4.31% vs the prior close of $12.52. Day range $12.43–$13.16, opened at $12.53.
- Volume was 974.90K shares, 0.8x its 50-day average of 1.25M.
- Price is -15.3% vs its 50-day average ($15.41).
- 52-week range $11.00–$22.67; today's close sits at 18% of that range, 42.4% below the 52-week high.
Oct 14, 2026 — GENB rises 2.1% to $12.52
- Closed at $12.52, +2.12% vs the prior close of $12.26. Day range $12.10–$12.90, opened at $12.61.
- Volume was 1.95M shares, 1.6x its 50-day average of 1.22M.
- Price is -18.9% vs its 50-day average ($15.44).
- 52-week range $11.00–$22.67; today's close sits at 13% of that range, 44.8% below the 52-week high.
Oct 13, 2026 — GENB slides 11.4% to $12.26, a 3-month low
- Closed at $12.26, -11.42% vs the prior close of $13.84. Day range $12.25–$13.75, opened at $13.75.
- Volume was 930.70K shares, 0.8x its 50-day average of 1.20M.
- Price is -20.8% vs its 50-day average ($15.47).
- 52-week range $11.00–$22.67; today's close sits at 11% of that range, 45.9% below the 52-week high.
Oct 12, 2026 — GENB slides 3.5% to $13.84
- Closed at $13.84, -3.49% vs the prior close of $14.34. Day range $13.81–$14.37, opened at $14.34.
- Volume was 675.90K shares, 0.6x its 50-day average of 1.20M — lighter than usual.
- Price is -10.8% vs its 50-day average ($15.52).
- 52-week range $11.00–$22.67; today's close sits at 24% of that range, 39.0% below the 52-week high.
Oct 9, 2026 — GENB rises 2.5% to $14.34
- Closed at $14.34, +2.50% vs the prior close of $13.99. Day range $13.94–$14.86, opened at $14.06.
- Volume was 903.10K shares, 0.8x its 50-day average of 1.19M.
- Price is -7.6% vs its 50-day average ($15.52).
- 52-week range $11.00–$22.67; today's close sits at 29% of that range, 36.7% below the 52-week high.
Oct 8, 2026 — GENB jumps 3.1% to $13.99
- Closed at $13.99, +3.10% vs the prior close of $13.57. Day range $13.08–$14.14, opened at $13.50.
- Volume was 1.16M shares, 1.0x its 50-day average of 1.18M.
- Price is -9.8% vs its 50-day average ($15.51).
- 52-week range $11.00–$22.67; today's close sits at 26% of that range, 38.3% below the 52-week high.
Oct 7, 2026 — GENB dips 1.7% to $13.57, a 1-month low
- Closed at $13.57, -1.67% vs the prior close of $13.80. Day range $13.35–$13.99, opened at $13.59.
- Volume was 926.30K shares, 0.8x its 50-day average of 1.19M.
- Price is -12.4% vs its 50-day average ($15.49).
- 52-week range $11.00–$22.67; today's close sits at 22% of that range, 40.1% below the 52-week high.
Oct 6, 2026 — GENB dips 0.8% to $13.80
- Closed at $13.80, -0.79% vs the prior close of $13.91. Day range $13.55–$14.19, opened at $14.00.
- Volume was 1.17M shares, 1.0x its 50-day average of 1.17M.
- Price is -10.9% vs its 50-day average ($15.49).
- 52-week range $11.00–$22.67; today's close sits at 24% of that range, 39.1% below the 52-week high.
Oct 5, 2026 — GENB rises 1.6% to $13.91
- Closed at $13.91, +1.61% vs the prior close of $13.69. Day range $13.45–$14.06, opened at $13.71.
- Volume was 1.12M shares, 1.0x its 50-day average of 1.16M.
- Price is -10.2% vs its 50-day average ($15.48).
- 52-week range $11.00–$22.67; today's close sits at 25% of that range, 38.6% below the 52-week high.
Oct 2, 2026 — GENB dips 0.8% to $13.69, a 1-month low, 3 down days in a row
- Closed at $13.69, -0.80% vs the prior close of $13.80. Day range $13.30–$14.30, opened at $13.93.
- Volume was 1.26M shares, 1.1x its 50-day average of 1.14M.
- Price is -11.5% vs its 50-day average ($15.47).
- 52-week range $11.00–$22.67; today's close sits at 23% of that range, 39.6% below the 52-week high.
- That makes 3 straight losses.
GENB latest news & SEC filings
Every SEC filing by or about GENB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Arnold Frances sold 1,000 shares at $16.00 (≈$16.00K) on Sep 1, 2026
- Arnold Frances sold 1,000 shares at $16.00 (≈$16.00K) on Sep 1, 2026
- Arnold Frances sold 1,000 shares at $16.00 (≈$16.00K) on Sep 1, 2026
- Arnold Frances sold 1,000 shares at $16.00 (≈$16.00K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $6.31M (prior year $10.13M) (-37.7% vs Jun 30, 2025)
- Net income: -$67.25M (prior year -$52.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.52 (prior year -$1.94) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade GENB
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.53% (largest 11.4%). That is a volatile stock.
- Liquidity: about 1.14M shares (≈$13.80M) trade per day on average.
- 52-week position: $12.09 vs a range of $11.00–$22.67 (9% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 21 open-market buys, 4 sales; latest: Frances Arnold sold 1,000 shares on Sep 1, 2026.
- Latest filings: 8-K Aug 26, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GENB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 13.02 | 13.22 | 11.84 | 12.09 | 1.07M |
| Oct 15, 2026 | 12.53 | 13.16 | 12.43 | 13.06 | 974.90K |
| Oct 14, 2026 | 12.61 | 12.90 | 12.10 | 12.52 | 1.95M |
| Oct 13, 2026 | 13.75 | 13.75 | 12.25 | 12.26 | 930.70K |
| Oct 12, 2026 | 14.34 | 14.37 | 13.81 | 13.84 | 675.90K |
| Oct 9, 2026 | 14.06 | 14.86 | 13.94 | 14.34 | 903.10K |
| Oct 8, 2026 | 13.50 | 14.14 | 13.08 | 13.99 | 1.16M |
| Oct 7, 2026 | 13.59 | 13.99 | 13.35 | 13.57 | 926.30K |
| Oct 6, 2026 | 14.00 | 14.19 | 13.55 | 13.80 | 1.17M |
| Oct 5, 2026 | 13.71 | 14.06 | 13.45 | 13.91 | 1.12M |
| Oct 2, 2026 | 13.93 | 14.30 | 13.30 | 13.69 | 1.26M |
| Oct 1, 2026 | 14.79 | 14.99 | 13.77 | 13.80 | 1.39M |
| Sep 30, 2026 | 15.54 | 15.61 | 15.00 | 15.02 | 733.20K |
| Sep 29, 2026 | 14.90 | 15.51 | 14.65 | 15.42 | 594.60K |
| Sep 28, 2026 | 15.15 | 15.32 | 14.61 | 14.91 | 1.14M |
| Sep 25, 2026 | 16.04 | 16.10 | 15.03 | 15.15 | 1.27M |
| Sep 24, 2026 | 16.44 | 16.48 | 15.40 | 15.99 | 1.44M |
| Sep 23, 2026 | 17.44 | 17.59 | 16.46 | 16.52 | 1.42M |
| Sep 22, 2026 | 17.68 | 17.97 | 17.32 | 17.46 | 1.31M |
| Sep 21, 2026 | 17.46 | 17.68 | 17.11 | 17.38 | 1.39M |
About Generate Biomedicines
Generate Biomedicines (GENB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOMERVILLE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2100782.
GENB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Noubar Afeyan | Director | Mar 2, 2026 |
| Frances Arnold | Director | Sep 3, 2026 |
| Stephane Bancel | Director | Mar 2, 2026 |
| Marsha Fanucci | Director | Mar 2, 2026 |
| Jane L Mendillo | Director | Mar 2, 2026 |
| Michael Nally | Chief Executive Officer | Mar 6, 2026 |
| Paul Gray Parker | Director | Mar 2, 2026 |
| Nancy A Simonian | Director | Mar 2, 2026 |
| Rupert Vessey | Director | Mar 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gevorg Grigoryan | Chief Technology Officer | Mar 2, 2026 |
| Beth Grous | Chief People Officer | Mar 2, 2026 |
| Aarif Khakoo | Chief Scientific Officer | Feb 26, 2026 |
| Laurie Anne Lee | Chief Medical Officer | Mar 2, 2026 |
| Sean Martin | Chief Legal Officer & GC | Mar 2, 2026 |
| Michael Nally | Chief Executive Officer | Mar 6, 2026 |
| Jason Silvers | President & CFO | Mar 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Frances Arnold | Sale | 1,000 | $16.00 |
| Sep 1, 2026 | Frances Arnold | Sale | 1,000 | $16.00 |
| Sep 1, 2026 | Frances Arnold | Sale | 1,000 | $16.00 |
| Sep 1, 2026 | Frances Arnold | Sale | 1,000 | $16.00 |
| Mar 4, 2026 | Michael Nally | Buy | 20,000 | $12.00 |
| Mar 4, 2026 | Michael Nally | Buy | 20,000 | $12.00 |
| Mar 4, 2026 | Michael Nally | Buy | 20,000 | $12.00 |
| Mar 4, 2026 | Michael Nally | Buy | 20,000 | $12.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Health Ltp Fund General Partner Llc Nutritional | Buy | 1,562,500 | $16.00 |
| Mar 2, 2026 | Pioneering Fund Vii General Partner Llc Flagship | Buy | 1,562,500 | $16.00 |
GENB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $561.69M, total liabilities $105.64M, cash $135.36M (as of Jun 30, 2026).
GENB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $13.89 |
| May 7, 2026 | 8-K Item 2.02 (results) | $13.59 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GENB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.